Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of California, Davis
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Weill Medical College of Cornell University
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
University of Washington
National Institutes of Health Clinical Center (CC)
Thomas Jefferson University
H. Lee Moffitt Cancer Center and Research Institute
Celgene
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Washington University School of Medicine
Celgene
University of Washington
Memorial Sloan Kettering Cancer Center
Regeneron Pharmaceuticals
National Cancer Institute (NCI)
Olivia Newton-John Cancer Research Institute
City of Hope Medical Center
Xynomic Pharmaceuticals, Inc.
Xynomic Pharmaceuticals, Inc.
Olivia Newton-John Cancer Research Institute
Oppilan Pharma Ltd
Ludwig-Maximilians - University of Munich